Shingles Vaccine

Vaccines to Prevent Shingles
Vaccine Basics

The only way to reduce the risk of developing shingles (herpes zoster) and the long-term pain that can follow shingles is to get vaccinated. You are at risk of shingles if you have had chickenpox. Shingles is caused by a reactivation of the chickenpox virus (called varicella zoster) in a person’s body.

The vaccine for shingles (Zostavax®) is licensed for use in people 60 years old and older to prevent shingles. The older a person is, the more severe the effects of shingles typically are—all adults 60 years old or older should get the shingles vaccine. The shingles vaccine is not recommended to treat active shingles or post-herpetic neuralgia (pain after the rash is gone) once it develops. Some people who get the shingles vaccine will develop a chickenpox-like rash near the place where they were vaccinated. As a precaution, this rash should be covered until it disappears.

About Shingles  What is Shingles (Herpes Zoster)?

The most common complication of shingles is a condition called postherpetic neuralgia (PHN). People with PHN have severe pain in the areas where they had the shingles rash, even after the rash clears up. The pain from PHN may be severe and debilitating, but it usually resolves in a few weeks or months in most patients.

Shingles usually starts as a painful rash on one side of the face or body. The rash forms blisters that typically scab over in seven to ten days and clears up within two to four weeks. Before the rash develops, there is often pain, itching, or tingling in the area where the rash will develop. This may happen anywhere from one to five days before the rash appears.

Most commonly, the rash occurs in a single stripe around either the left or the right side of the body. In other cases, the rash occurs on one side of the face. In rare cases (usually among people with weakened immune systems), the rash may be more widespread and look similar to a chickenpox rash. Shingles can affect the eye and cause loss of vision.

Who gets Shingles (Herpes Zoster)?  Almost one out of every three people in the United States will develop shingles, also known as zoster or herpes zoster. There are an estimated one million cases each year in this country.

People who have medical conditions that keep their immune systems from working properly, such as certain cancers, including leukemia and lymphoma, and human immunodeficiency virus (HIV), and people who receive immunosuppressive drugs, such as steroids and drugs given after organ transplantation are also at greater risk of getting shingles.

Read more about the shingles vaccine: shingles vaccine ; approved prescribing information ; CDC’s Shingles Vaccination Page ; reading about what to expect.

Article on Daliresp for COPD from Patient's Experience

Living Life to the Fullest -February 10th, 2012 | Author: Katelyn Harding

Chris Huckstepp says he first noticed deterioration in his lung function in 1994. “I was running for a train and when I just managed to get on as the doors closed, I felt so out of breath and oxygen I thought I was going to die,” he says. At the time, he was living in the UK and it was then he was diagnosed with emphysema and told to stop smoking by his doctor, which he did.

“My so-called ‘emphysema’ slowly got worse over the years, and in 2000 I had moved to the U.S. and signed on with a pulmonary specialist here,” Huckstepp says. “In 2001 I was asked if I had ever taken a genetic test for my emphysema, which I hadn’t, and that’s when I found out I had Alpha-1.” Huckstepp was prescribed an Alpha 1-proteinase inhibitor, which he says has been effective in significantly lowering his rate of lung deterioration.

“Since then, some things had to change. I’ve stopped playing tennis, and I find it difficult to walk and talk at the same time. Every now and again I have to stop and catch my breath.”

In July of last year, Huckstepp began taking Daliresp (Roflumilast), a pill taken daily to decrease the frequency of exacerbations. It was approved in 2011 by the Food and Drug Administration and is an inhibitor of an enzyme called phosphodiesterase type 4 (PDE-4). It represents the first new class of drugs that has been developed for COPD in more than 20 years.

“I talked to my doctor about it and started taking it in July and almost immediately I had a significant improvement in my breathing—to the point I could do daily exercises without a recovery period,” he says.

“That is the good side of Daliresp. But, there are side effects including upset stomach, inability to sleep, and a feeling of exhaustion and complete lack of energy. When my doctor prescribed this, he warned me about these side effects—another which is weight loss.”

Huckstepp, 57, says that since being diagnosed, the challenges he’s faced have been the inability to play sports and activities like before—the physical aspect of his life having been infringed upon. A smoker of about 30 years, he says when he started taking Daliresp, he was shocked by the severity of the side effects.

“After a week, I was pretty convinced I would stop taking it. I went back to my doctor and he did some oxygen level tests. After a couple weeks we talked again, and the nastier side effects had gone away,” he says. “I saw significant changes in my breathing, and it was worth putting up with the side effects. The weight loss was, in my case, a benefit which probably contributed to my improved stamina.”

Huckstepp says he believes that what has had a big influence on the quality of one’s life is how people perceive themselves.  “If you perceive yourself as a victim, it will reduce your quality of life significantly. If others perceive you as a victim it will reduce your quality of life even more. Life should be lived to the fullest, in spite of your limitations.”

DALIRESP http://www.daliresp.com/ is a prescription medicine used in adults with severe COPD to decrease their number of flare-ups or the worsening of COPD symptoms (exacerbations). For more information about it, please consult your doctor.

Glaxo starting first US inhaler recycling program

TRENTON, N.J. (AP) — Patients who use respiratory inhalers will be able to recycle the devices for the first time in the U.S., according to British drugmaker GlaxoSmithKline PLC, which is launching its “Complete the Cycle” program in drugstores in 31 cities.

GlaxoSmithKline is the top seller of respiratory medicines in the U.S., with brands including the blockbuster Advair, but its new program will also recycle inhalers made by competitors. The program, starting in cities from Anchorage, Alaska, to Atlanta, will enable patients to drop off inhalers in boxes at participating pharmacies. When bags inside the boxes are full, they’ll be shipped to a Glaxo recycling contractor.

“We expect to bring back at least 100,000 inhalers in the 31 markets” in the first year, Jorge Bartolome, Glaxo’s senior vice president for its respiratory business, told The Associated Press in an exclusive interview.  http://bit.ly/RqPGwd   http://us.gsk.com/html/responsibility/complete-the-cycle.html